Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LQDA 
Liquidia Technologies Inc (LQDA)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: LQDA (4-star) is a STRONG-BUY. BUY since 35 days. Simulated Profits (35.07%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $36.67
1 Year Target Price $36.67
| 6 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 101.69% | Avg. Invested days 39 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.24B USD | Price to earnings Ratio - | 1Y Target Price 36.67 |
Price to earnings Ratio - | 1Y Target Price 36.67 | ||
Volume (30-day avg) 10 | Beta 0.23 | 52 Weeks Range 9.68 - 29.94 | Updated Date 09/14/2025 |
52 Weeks Range 9.68 - 29.94 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.82 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -424.41% |
Management Effectiveness
Return on Assets (TTM) -39.74% | Return on Equity (TTM) -389.13% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2264477889 | Price to Sales(TTM) 115.8 |
Enterprise Value 2264477889 | Price to Sales(TTM) 115.8 | ||
Enterprise Value to Revenue 117.2 | Enterprise Value to EBITDA -9.43 | Shares Outstanding 86091504 | Shares Floating 60859771 |
Shares Outstanding 86091504 | Shares Floating 60859771 | ||
Percent Insiders 13.61 | Percent Institutions 70.58 |
Upturn AI SWOT
Liquidia Technologies Inc
Company Overview
History and Background
Liquidia Technologies Inc. was founded in 2004. It is a biopharmaceutical company focused on the development and commercialization of novel products that address unmet needs in pulmonary hypertension and other applications. They have primarily focused on their PRINT technology platform.
Core Business Areas
- Pulmonary Hypertension: Development and commercialization of inhaled therapies for pulmonary hypertension, including Yutrepia (treprostinil) inhalation powder.
Leadership and Structure
Damian deGoa leads as CEO. The company has a typical organizational structure with departments focused on research, development, clinical trials, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Yutrepia (treprostinil) inhalation powder: Inhaled therapy for pulmonary hypertension. Market share is still developing post-approval. Competitors include United Therapeutics' Tyvaso and various generics of treprostinil.
Market Dynamics
Industry Overview
The pulmonary hypertension market is characterized by significant unmet needs and increasing treatment options. The market is driven by a growing prevalence of the disease and advancements in therapeutic interventions.
Positioning
Liquidia aims to establish itself as a key player in the pulmonary hypertension market with Yutrepia, leveraging its PRINT technology. Its competitive advantage lies in the potential for improved efficacy and convenience compared to existing therapies.
Total Addressable Market (TAM)
The TAM for pulmonary hypertension is estimated to be several billion dollars. Liquidia's Yutrepia is targeting a portion of the PAH inhaled treprostinil market.
Upturn SWOT Analysis
Strengths
- Proprietary PRINT technology
- Yutrepia FDA approval
- Experienced management team
Weaknesses
- Limited commercial infrastructure
- Dependence on Yutrepia for revenue
- Ongoing patent litigation
Opportunities
- Expansion of Yutrepia market share
- Development of new therapies using PRINT technology
- Partnerships and collaborations
Threats
- Competition from established players
- Patent challenges
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- UTHR
- VTRS
- ALNY
Competitive Landscape
Liquidia faces significant competition from established players like United Therapeutics. Its advantages include the potential for improved efficacy and convenience of Yutrepia, while its disadvantages include limited commercial infrastructure and ongoing patent litigation.
Growth Trajectory and Initiatives
Historical Growth: Liquidia's historical growth has been primarily driven by R&D progress and clinical trial results. With the recent approval of Yutrepia, growth is expected to accelerate.
Future Projections: Future growth depends heavily on the successful commercialization of Yutrepia and the development of other pipeline products. Analyst estimates vary widely.
Recent Initiatives: Key initiatives include the commercial launch of Yutrepia, ongoing clinical trials, and efforts to defend its patents.
Summary
Liquidia Technologies is a biopharmaceutical company with promising product Yutrepia recently approved for Pulmonary Arterial Hypertension. The company's strengths lie in its proprietary PRINT technology and an experienced management team. However, it faces significant competition and ongoing patent litigation, but the successful launch and market penetration of Yutrepia will be critical to its future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Press Releases
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Liquidia Technologies Inc
Exchange NASDAQ | Headquaters Morrisville, NC, United States | ||
IPO Launch date 2018-07-26 | CEO & Director Dr. Roger A. Jeffs Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 170 | Website https://www.liquidia.com |
Full time employees 170 | Website https://www.liquidia.com | ||
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.